{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:39:51Z","timestamp":1773099591739,"version":"3.50.1"},"reference-count":33,"publisher":"Universa BV","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Background and aims: Tenofovir alafenamide fumarate (TAF) was shown equally efficacious in suppressing hepatitis B virus (HBV) but with less renal toxicity than tenofovir disoproxil fumarate (TDF). The aim of this real-world study was to evaluate renal function in post-liver transplantation (LT) patients that changed TDF with TAF.\n\nMethods: The TAF group (n=17) included patients who switched to TAF due to low (&lt;60 ml\/min\/1.73m2) Glomerular Filtration Rate (GFR). The control group included patients that remained on TDF (n=30), although some (n= 14) had chronic kidney disease (CKD) (TDF-CKD group). GFR was assessed using: i) MDRD-6 variable; ii) CKD-EPI formula; iii) radionuclide technique (rGFR).\n\nResults: There were no significant differences between the two groups except for the presence of diabetes and follow-up period, which were more common and shorter, respectively, in the TAF group (35% vs. 10%, p=0.03; 13.7 vs. 35.5 months, p&lt;0.001). At the end of follow-up there were no significant changes in renal function between the TAF and the TDF group or TDF-CKD group, although the numerical change in rGFR in the latter comparison was greater in the TAF group (\u0394rGFR 3 vs. -2.14 ml\/min, p=0.26). The use of everolimus was associated with improvement in renal function (\u0394rGFR 2 vs. -7.75 ml\/min, p=0.06 [TAF vs. TDF group]; 2 vs. -12 ml\/min, p=0.01 [TAF vs. TDF-CKD group]). There were no TAF- related side effects or cases of HBV recurrence.\n\nConclusion: Conversion to TAF in post-LT patients who develop CKD does not lead to improvement of kidney function after a period of one year.<\/jats:p>","DOI":"10.51821\/85.2.9577","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T15:05:59Z","timestamp":1668006359000},"page":"331-337","source":"Crossref","is-referenced-by-count":1,"title":["Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease"],"prefix":"10.51821","volume":"85","author":[{"given":"E","family":"Sinakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Panas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Fragkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Antoniadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Tsakni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Notopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Tsoulfas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Akriviadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"LAMPERTICO P, AGARWAL K, BERG T, BUTI M, JANSSEN HLA, PAPATHEODORIDIS G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017, 67(2): 370-98.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"AGARWAL K, BRUNETTO M, SETO WK, LIM Y-S, FUNG S, MARCELLIN P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018, 68(4): 672-81.","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"BROUWER WP. Tenofovir alafenamide for hepatitis B: evolution or revolution? lancet Gastroenterol Hepatol. 2016, 1(3): 174-5.","DOI":"10.1016\/S2468-1253(16)30083-8"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"WONG GL-H, SETO W-K, WONG VW-S, YUEN M-F, CHAN HL-Y. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018, 47(6): 730-7.","DOI":"10.1111\/apt.14497"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"COOPER RD, WIEBE N, SMITH N, KEISER P, NAICKER S, TONELLI M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010, 51(5): 496-505.","DOI":"10.1086\/655681"},{"key":"ref5","unstructured":"KARA AV, YILDIRIM Y, OZCICEK F, ALDEMIR MN, ARSLAN Y, BAYAN K, et al. Effects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic hepatitis B patients. Acta Gastroenterol Belg. 2019, 82(2): 273-7."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"WONG GL-H, TSE Y-K, WONG VW-S, YIP TC-F, TSOI KK-F, CHAN HL-Y. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology. 2015, 62(3): 684-93.","DOI":"10.1002\/hep.27894"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"RODRIGUEZ-NOVOA S, ALVAREZ E, LABARGA P, SORIANO V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010, 9(4): 545-59.","DOI":"10.1517\/14740331003627458"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"OJO AO, HELD PJ, PORT FK, WOLFE RA, LEICHTMAN AB, YOUNG EW, et al. Chronic Renal Failure after Transplantation of a Nonrenal Organ. N Engl J Med. 2003, 349(10): 931-40.","DOI":"10.1056\/nejmoa021744"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"PERUMPAIL R, KHEMICIAN S, LAKHOO K, DO A, CHOI G, DURAZO F, et al. PS-049-Tenofovir alafenamide for hepatitis B virus prophylaxis post-liver transplantation is associated with improved renal function: An interim analysis of a multicenter real-world experience. J Hepatol. 2019, 70(1): e30-1.","DOI":"10.1016\/s0618-8278(19)30055-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"GANE EJ GB, RAY-CHADHURI D et al. Safety and Efficacy at 1 Year in Post\u2012Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis. Hepatology. 2018, 68(S1): 1-183.","DOI":"10.1016\/S0168-8278(18)31276-5"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"SRIPONGPUN P, MANNALITHARA A, KWO PY, KIM WR. Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clin Gastroenterol Hepatol. 2020, 18(3): 747-9.","DOI":"10.1016\/j.cgh.2019.05.057"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"LEVEY AS. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Ann Intern Med. 1999, 130(6): 461.","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"LEVEY AS, STEVENS LA, SCHMID CH, ZHANG Y (Lucy), CASTRO AF, FELDMAN HI, et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009, 150(9): 604.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"FLEMING JS, NUNAN TO. The new BNMS guidelines for measurement of glomerular filtration rate. Nucl Med Commun. 2004, (8): 755-7","DOI":"10.1097\/01.mnm.0000136714.77658.4a"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"LEVEY AS, CORESH J. Chronic kidney disease. Lancet. 2012, 379(9811): 165-80.","DOI":"10.1016\/s0140-6736(11)60178-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"WATT KDS, PEDERSEN RA, KREMERS WK, HEIMBACH JK, CHARLTON MR. Evolution of Causes and Risk Factors for Mortality Post-Liver Transplant: Results of the NIDDK Long-Term Follow-Up Study. Am J Transplant. 2010, 10(6): 1420-7.","DOI":"10.1111\/j.1600-6143.2010.03126.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"CHOLONGITAS E, PAPATHEODORIDIS GV. High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review. Am J Transplant. 2013, 13(2): 353-62.","DOI":"10.1111\/j.1600-6143.2012.04315.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"LEE J, PARK JY, YANG SJ, LEE JY, KIM DG, JOO DJ, et al. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. J Viral Hepat. 2020, 27(8): 818-25.","DOI":"10.1111\/jvh.13291"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"MURAKAMI E, WANG T, PARK Y, HAO J, LEPIST E-I, BABUSIS D, et al. Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy. Antimicrob Agents Chemother. 2015, 59(6): 3563-9.","DOI":"10.1128\/aac.00128-15"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"AGARWAL K, FUNG SK, NGUYEN TT, CHENG W, SICARD E, RYDER SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015, 62(3): 533-40.","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"CHAN HLY, FUNG S, SETO WK, CHUANG W-L, CHEN C-Y, KIM HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016, 1(3): 185-95.","DOI":"10.1016\/s2468-1253(16)30024-3"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"BUTI M, GANE E, SETO WK, CHAN HLY, CHUANG W-L, STEPANOVA T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016, 1(3): 196-206.","DOI":"10.1016\/s2468-1253(16)30107-8"},{"key":"ref23","unstructured":"KAY W, SETO WK, IZUMI N, LIM YS, KAO JH, STREINU-CERCEL A, et al. Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF). Hepatology. 2018, 68(S1): 1-183."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"LUCEY MR, TERRAULT N, OJO, HAY JE, NEUBERGER J, BLUMBERG E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplant. 2013, 19(1): 3-26.","DOI":"10.1002\/lt.23566"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"TRAYNOR J, MACTIER R, GEDDES CC, FOX JG. How to measure renal function in clinical practice. BMJ. 2006, 333(7571): 733-7.","DOI":"10.1136\/bmj.38975.390370.7c"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"PIANO S, ROMANO A, DI PASCOLI M, ANGELI P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017, 37: 116-22.","DOI":"10.1111\/liv.13305"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"MCMEEKIN H, BARNFIELD M, WICKHAM F, BURNISTON M. 99mTc DTPA vs. 51Cr EDTA for glomerular filtration rate measurement. Nucl Med Commun. 2019, 40(12): 1224-9.","DOI":"10.1097\/mnm.0000000000001101"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"SAAB S, SONG D, CHALLITA YP, XIWEN ZHOU T, SAAB EG, VIRAMONTES MR, et al. Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B. Clin Transplant. 2019, 33(12).","DOI":"10.1111\/ctr.13740"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"CHOLONGITAS E, GOULIS I, THEOCHARIDOU E, ANTONIADIS N, FOUZAS I, IMVRIOS G, et al. Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience. Ann Gastroenterol. 2018, 31(5): 613-20","DOI":"10.20524\/aog.2018.0278"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"CHOLONGITAS \u0395, GOULIS I, THEOCHARIDOU E, ANTONIADIS N, FOUZAS I, GIAKOUSTIDIS D, et al. Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience. Hepatol Int. 2014, 8(1): 137-45.","DOI":"10.1007\/s12072-013-9492-6"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"SALIBA F, DUVOUX C, GUGENHEIM J, KAMAR N, DHARANCY S, SALAME E, et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. Am J Transplant. 2017, 17(7): 1843-52.","DOI":"10.1111\/ajt.14212"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"SALIBA F, DUVOUX C, DHARANCY S, DUMORTIER J, CALMUS Y, GUGENEHEIM J, et al. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years. Liver Transplant. 2019, 25(12): 1822-32.","DOI":"10.1002\/lt.25664"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T15:07:22Z","timestamp":1668006442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2011\/Tenofovir%20alafenamide%20prophylaxis%20post-liver%20transplantation:%20a%20real-world%20study%20in%20patients%20with%20chronic%20kidney%20disease\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.51821\/85.2.9577","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}